Program
carfilzomib
Also written as “Carfilzomib”, “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)” and “Drug: Carfilzomib + Dexamethasone”.
Its studies are mostly in Multiple Myeloma · Amyloidosis · Small Cell Lung Carcinoma · Waldenstrom Macroglobulinemia · Hematologic Neoplasms, led by 5 companies.
Drug pageCarfilzomib: every studyMany companies study it; this page follows only the 33 they lead. All 157 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 230 open or running | phase 4since Apr 16, 2019 | Sep 6, 2005 | none ahead |
| AbbVieits history only | 32 open or running | phase 3since Nov 28, 2023 | Sep 27, 2013 | Jun 2027phase 2 · NCT02899052 |
| Criteriumits history only | 30 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Oncotherapeuticsits history only | 20 open or running | phase 2since Jan 3, 2013 | Jan 3, 2013 | none ahead |
| Sanofi | 22 open or running | phase 2since Jan 20, 2023 | Jan 20, 2023 | Apr 1, 2027phase 2 · NCT06356571 |
Also a collaborator on its studies: Bristol-Myers Squibb and Onyx Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT05704049 · 118 enrolled · Australia, Brazil, China and more
- Apr 5, 2024Phase 2 study in Plasma Cell Myeloma RefractoryNCT06356571 · 64 enrolled · United States
- Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractoryNCT06356571
TargetBeta
“26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bortezomibrule | Johnson & Johnson | phase 4 | 85 |
Studies
All 2 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06356571Plasma Cell Myeloma Refractory · United States | 2 | Active, not recruiting | Apr 1, 2027 | 64 |
| NCT05704049Multiple Myeloma · Australia, Brazil, China and more | 2 | Active, not recruiting | Dec 22, 2025 | 118 |
How it is read
Names in the registry
- “Carfilzomib”, 34 entries
- “carfilzomib”, 3 entries
- “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)”, 1 entry
- “Drug: Carfilzomib + Dexamethasone”, 1 entry
- “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 33 studies
- Amyloidosis, 1 study
- Small Cell Lung Carcinoma, 1 study
- Waldenstrom Macroglobulinemia, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.